EP08.01-105 Efficacy of First-Line Immune Checkpoint Inhibitors in Patients with Advanced NSCLC Harboring KRAS, MET, FGFR, RET, BRAF, and HER2 Alterations

In patients with NSCLC harboring molecular alterations, the efficacy of immune checkpoint inhibitors (ICI) remains unknown. The aim of our study was to examine the efficacy of first-line ICI among patients having NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations, compared to those with driver-unknown.